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PCLINICAL RESEARCH Focus Issue: Substudies From ExTRACT-TIMI 25
Percutaneous Coronary Intervention in Patients
Receiving Enoxaparin or Unfractionated Heparin
After Fibrinolytic Therapy for ST-Segment Elevation
Myocardial Infarction in the ExTRACT-TIMI 25 Trial
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Objectives We sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UFH) as adjunctive therapy
for patients with ST-segment elevation myocardial infarction (STEMI) who receive fibrinolytic therapy and subsequently un-
dergo percutaneous coronary intervention (PCI) by analyzing data from the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction 25) trial.
Background Limited data are available on the use of ENOX compared with UFH as adjunctive therapy in STEMI patients
treated with fibrinolytic therapy and subsequent PCI.
Methods A total of 20,479 STEMI patients who received fibrinolytic therapy were randomized to a strategy of ENOX
throughout index hospitalization or UFH for at least 48 h, with blinded study drug to continue if PCI was per-
formed. The primary end point of death or recurrent MI through 30 days was compared for ENOX versus UFH
among the patients who underwent subsequent PCI (n  4,676).
Results After initial fibrinolysis, fewer patients underwent PCI through 30 days in the ENOX versus the UFH group (22.8%
vs. 24.2%; p  0.027). Among patients who underwent PCI by 30 days, the primary end point occurred in 10.7%
of ENOX and 13.8% of UFH patients (0.77 relative risk; p  0.001). There were no differences in major bleeding
for ENOX versus UFH (1.4% vs. 1.6%; p  NS). Results were similar when PCI was carried out in patients receiv-
ing blinded study drug during PCI (n  2,178).
Conclusion Among patients treated with fibrinolytic therapy for STEMI who underwent subsequent PCI, ENOX administration
was associated with a reduced risk of death or recurrent MI without difference in the risk of major bleeding. The
strategy of ENOX support for fibrinolytic therapy followed by PCI is superior to UFH and provides a seamless tran-
sition from the medical management to the interventional management phase of STEMI without the need for
introducing a second anticoagulant in the cardiac catheterization laboratory. (J Am Coll Cardiol 2007;49:
2238–46) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.093fi
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Compared with primary percutaneous coronary
intervention (PCI), fibrinolytic therapy for
ST-segment elevation myocardial infarction
(STEMI) is limited by recurrent MI, bleeding,
and the risk of intracranial hemorrhage (1). One
approach to limit the risk of reinfarction following
brinolytic agent administration is the performance of PCI,
See page 2247
ut data supporting this approach are conflicting (2–5). Older
tudies indicated that PCI after fibrinolytic agent administra-
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June 12, 2007:2238–46 PCI in the ExTRACT-TIMI 25 Trialion was associated with an increased risk of adverse outcomes
2–5). However, newer adjunctive pharmacotherapies and
mproved interventional devices may reduce the hazard asso-
iated with PCI after fibrinolytic agent administration (6), and
ontemporary trial databases offer the opportunity to re-
valuate the approach of performing PCI in patients who
reviously received a fibrinolytic.
The ExTRACT-TIMI 25 (Enoxaparin and Thrombol-
sis Reperfusion for Acute Myocardial Infarction Treat-
ent–Thrombolysis In Myocardial Infarction 25) trial com-
ared a strategy of enoxaparin (ENOX) with unfractionated
eparin (UFH) as adjunctive therapy for fibrinolysis among
TEMI patients (7,8). The present prospectively planned
nalysis of the ExTRACT-TIMI 25 trial evaluated the
ypothesis that a strategy of ENOX for the duration of the
ndex hospitalization is superior to UFH as adjunctive
herapy for fibrinolytic therapy among patients who subse-
uently undergo PCI.
ethods
atient population. The STEMI patients treated with fi-
rinolytic agents were randomized in 48 countries (7,8). Eligible
atients were at least 18 years of age, had at least 20 min of
schemic symptoms while at rest within 6 h before randomization,
ad ST-segment elevation of at least 0.1 mV in 2 limb leads or
Figure 1 Study Profile
Number of patients in the enoxaparin (ENOX) and unfractionated heparin (UFH) gro
with coronary artery bypass graft (CABG), medical therapy, and percutaneous coronf 0.2 mV in at least 2 contiguous
recordial leads or left bundle-
ranch block, and were scheduled to
ndergo fibrinolysis.
tudy protocol. After treatment
ith a fibrinolytic agent and as-
irin, patients were randomized
o either ENOX or UFH in a
ouble-blind double-dummy de-
ign to continue until hospital
ischarge or a maximum of 8
ays (whichever came first) as
reviously described (7).
Patients undergoing PCI were to receive antithrombotic
upport with blinded study drug. Before PCI, a blinded dose
f 0.3 mg/kg of ENOX (or matched placebo) was admin-
stered intravenously if the last subcutaneous dose was 8 to
2 h earlier, whereas no additional ENOX (or matched
lacebo) was administered if the last subcutaneous dose was
dministered within the preceding 8 h. Unfractionated
eparin (or matched placebo) was dosed according to the
ctivated clotting time, using a target of 200 s for patients
eceiving and 250 s for those not receiving a glycoprotein
Ib/IIIa inhibitor. The activated clotting time was encrypted
o as not to break the blinding. All monitoring of antico-
gulation to adjust the dose of UFH to maintain an
eated
tervention (PCI).
Abbreviations
and Acronyms
ENOX  enoxaparin
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
UFH  unfractionated
heparinups tr
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PCI in the ExTRACT-TIMI 25 Trial June 12, 2007:2238–46ctivated partial thromboplastin time of 1.5 to 2.0 times the
ontrol value was performed in a blinded fashion by per-
onnel caring for the patient or in an unblinded fashion by
designated medical professional not involved in the
atient’s care. If a closure device was used, the sheath was to
e removed at the end of the PCI; however, if no closure
evice was used, the sheath was to be removed at least 6 h
fter the last intravenous or subcutaneous dose of blinded
tudy drug. The blinded study medication was not to be
estarted after uncomplicated PCI procedures but was to be
estarted after groin hemostasis was achieved in patients in
hom antithrombotic therapy was considered necessary
linically.
Although PCI could be performed at any time for failed
brinolysis or in response to an episode of recurrent MI/
schemia, the protocol recommended that elective proce-
ures be deferred for at least 48 h after randomization. For
CI performed after day 8 or hospital discharge, open-label
FH was to be used irrespective of the original treatment
ssignment. Clopidogrel was administered at the investiga-
aseline Characteristics by Performance of PCI by 30 Days
Table 1 Baseline Characteristics by Performance of PCI by 30
PC
Baseline characteristics
Age, yrs
Age 75 yrs, n (%)
Male gender, n (%)
White race, n (%) 3,801/
Weight, kg
Hypertension, n (%) 1,733/
Hyperlipidemia, n (%) 965/
Current smoker, n (%) 2,388/
Diabetes mellitus, n (%) 755/
Prior MI, n (%) 514/
Prior angina pectoris, n (%) 992/
Prior PCI, n (%) 290/
Index presentation and medications
Anterior MI, n (%) 1,889/
Chronic treatment with aspirin, n (%) 730/
UFH within 3 h before randomization, n (%) 931/
LMWH within 7 days before randomization, n (%)
Creatinine clearance, ml/min
Killip classification II, n (%) 393/
TIMI risk score 3, n (%) 1,247/
Time from symptom onset to start of fibrinolytic therapy, h
Fibrinolytic agent
Fibrin-specific, n (%)
Streptokinase, n (%)
Cardiac medications during index hospitalization
Aspirin, n (%)
Clopidogrel, n (%)
Beta-blockers, n (%)
ACE inhibitors or angiotensin-receptor blockers, n (%)
Statin, n (%)
GP IIb/IIIa inhibitors, n (%)
ontinuous variables are shown as median (interquartile range).
ACE  angiotensin-converting enzyme; GP  glycoprotein; LMWH  low-molecular-weight heparin; M
yocardial Infarction; UFH  unfractionated heparin.or’s discretion. Patients were followed for clinical end
oints and adverse events during the index hospitalization
nd at day 30 (range day 31 to day 38) in person or by
elephone.
nd points. The prespecified primary efficacy end point of
he trial and of this substudy was the composite of all-cause
ortality or nonfatal recurrent MI through 30 days (7). The
dditional secondary end point of net clinical benefit was the
omposite of death or recurrent nonfatal MI or nonfatal
IMI major bleed. All ischemic and clinically significant
leeding events were adjudicated by a blinded independent
linical events committee using prespecified definitions
7,8).
The main analysis included patients who underwent PCI
y 30 days. An additional analysis was conducted in patients
ho underwent PCI while receiving double-blind study
rug.
tatistical analysis. All efficacy and net clinical benefit
omparisons were analyzed by the intention-to-treat prin-
iple. All safety analyses were performed according to the
4,676) No PCI (n  15,223) p Value
(50, 66) 60 (51, 70) 0.001
(7.3) 2,154 (14.2) 0.001
(82.5) 11,332 (74.4) 0.001
(81.3) 13,584/15,222 (89.2) 0.001
(69, 85.1) 76 (68, 85) 0.03
(37.4) 6,935/15,027 (46.2) 0.001
(22.7) 1,808/11,195 (16.2) 0.001
(51.1) 7,068/15,214 (46.5) 0.001
(16.3) 2,176/15,037 (14.5) 0.003
(11.0) 2,066/15,168 (13.6) 0.001
(21.3) 4,551/15,122 (30.1) 0.001
(6.2) 344/15,215 (2.3) 0.001
(40.6) 6,792/15,098 (45.0) 0.001
(15.7) 1,908/15,192 (12.6) 0.001
(19.9) 2,172/15,222 (14.3) 0.001
(0.7) 58 (0.4) 0.01
(69.2, 107.9) 80.6 (61.7, 103.4) 0.001
(8.4) 1,854/15,219 (12.2) 0.001
(27.1) 5,789/15,109 (38.3) 0.001
(1.8, 3.9) 3.3 (2.3, 4.3) 0.001
0.001
(78.6) 12,143 (79.7)
(20.9) 3,047 (20.0)
(97.6) 14,353 (94.3) 0.001
(67.6) 2,356 (15.5) 0.001
(86.1) 13,020 (85.5) 0.30
(80.1) 12,111 (79.6) 0.45
(85.3) 9,734 (63.9) 0.001
(17.3) 55 (0.4) 0.001Days
I (n 
57
339
3,856
4,676
76
4,631
4,257
4,675
4,639
4,660
4,648
4,668
4,659
4,666
4,676
31
87.1
4,669
4,595
2.7
3,678
976
4,563
3,160
4,028
3,744
3,987
811I  myocardial infarction; PCI  percutaneous coronary intervention; TIMI  Thrombolysis In
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June 12, 2007:2238–46 PCI in the ExTRACT-TIMI 25 Trialreatment actually received by the patient. For patients who
nderwent more than 1 PCI, the first procedure was
ounted as the index procedure in the analysis. Patients who
ropensity to Undergo PCI by 30 Days*
Table 2 Propensity to Undergo PCI by 30 Days*
Odds Ratio (95% CI) p Value
Age (10 yrs) 0.81 (0.78–0.84) 0.001
SBP (10 mm Hg) 1.03 (1.01–1.05) 0.003
Heart rate (10 beats/min) 0.93 (0.91–0.95) 0.001
Time from symptom onset to fibrinolytic (h) 0.93 (0.90–0.95) 0.001
Gender (male) 1.20 (1.08–1.33) 0.001
History of hypertension 1.15 (1.06–1.26) 0.001
Prior MI 0.85 (0.73–0.98) 0.030
Prior PCI 1.47 (1.20–1.81) 0.001
Prior aspirin use 1.13 (1.01–1.26) 0.042
Anterior MI 1.08 (1.00–1.17) 0.053
Randomized to ENOX compared with UFH 0.91 (0.84–0.98) 0.011
Model also includes individual countries, which are not shown owing to space constraints.
CI confidence interval; ENOX enoxaparin; SBP systolic blood pressure; other abbreviations
s in Table 1.
aseline Characteristics by Treatment Group Among Patients Unde
Table 3 Baseline Characteristics by Treatment Group Among P
EN
Baseline characteristics
Age, yrs
Age 75 yrs, n (%)
Male gender, n (%)
White race, n (%)
Weight, kg
Hypertension, n (%) 869
Hyperlipidemia, n (%) 454
Current smoker, n (%) 1,171
Diabetes mellitus, n (%) 368
Prior MI, n (%) 246
Prior angina pectoris, n (%) 481
Prior PCI, n (%) 147
Index presentation and medications
Anterior MI, n (%) 925
Chronic treatment with aspirin, n (%) 369
UFH within 3 h before randomization, n (%)
LMWH within 7 days before randomization, n (%)
Creatinine clearance, ml/min
Killip classification II, n (%) 180
TIMI risk score 3, n (%) 615
Time from symptom onset to start of fibrinolytic therapy, h
Fibrinolytic agent
Fibrin-specific, n (%)
Streptokinase, n (%)
Cardiac medications during index hospitalization
Aspirin, n (%)
Clopidogrel, n (%)
Beta-blockers, n (%)
ACE inhibitors or angiotensin-receptor blockers, n (%)
Statin, n (%)
GP IIb/IIIa inhibitors, n (%)
PCI performed on blinded study drug, n (%)ontinuous variables are shown as median (interquartile range).
Abbreviations as in Tables 1 and 2.nderwent coronary artery bypass grafting were excluded
rom the analysis. In the comparison of baseline character-
stics, differences in continuous variables were analyzed
sing the Wilcoxon rank sum test, and differences in
ategoric variables were analyzed using the chi-square test.
linical event data are reported as percentages and relative
isk comparing ENOX and UFH. For the primary end
oint, multivariate analysis was performed using a logistic
egression model (results displayed as adjusted [ORadj]) that
ncluded terms for treatment group, age, earlier aspirin use,
moking, time from symptom onset to fibrinolytic agent,
ype of fibrinolytic agent used (fibrin-specific or streptoki-
ase), duration of antithrombin therapy before PCI, and the
ropensity to undergo PCI. The propensity score was
onstructed by applying a forward selection algorithm with
n inclusion p value threshold of 0.05 to a logistic
egression model predicting PCI in the entire trial cohort
nd containing candidate baseline variables that included
emographics, traditional cardiovascular risk factors, earlier
g PCI by 30 Days
ts Undergoing PCI by 30 Days
 2,272) UFH (n  2,404) p Value
(50, 66) 57 (49, 66) 0.45
(7.2) 175 (7.3) 0.94
(82.2) 1,989 (82.7) 0.61
(81.2) 1,958 (81.5) 0.78
(69, 86) 77 (69, 85) 0.44
(38.6) 864/2,382 (36.3) 0.10
(22.0) 511/2,195 (23.3) 0.33
(51.5) 1,217/2,403 (50.7) 0.54
(16.3) 387/2,385 (16.2) 0.93
(10.9) 268/2,394 (11.2) 0.71
(21.3) 511/2,391 (21.4) 0.96
(6.5) 143/2,401 (6.0) 0.46
(40.9) 964/2,396 (40.2) 0.66
(16.3) 361/2,400 (15.0) 0.24
(20.7) 460 (19.1) 0.17
(0.5) 19 (0.8) 0.27
(69.1, 107.5) 88.14 (69.3, 108.2) 0.43
(7.9) 213/2,403 (8.9) 0.26
(27.7) 632/2,373 (26.6) 0.43
(1.8, 4.0) 2.8 (1.8, 3.9) 0.77
0.81
(78.3) 1,899 (79.0)
(21.1) 496 (20.6)
(97.1) 2,356 (98.0) 0.05
(66.2) 1,656 (68.9) 0.05
(86.1) 2,071 (86.2) 0.99
(80.6) 1,912 (79.5) 0.35
(84.7) 2,063 (85.8) 0.28
(15.4) 461 (19.2) 0.001
(11.3) 1,075 (11.0) 0.53rgoin
atien
OX (n
57
164
1,867
1,843
76
/2,249
/2,062
/2,272
/2,254
/2,266
/2,257
/2,267
/2,263
/2,266
471
12
86.3
/2,266
/2,222
2.7
1,779
480
2,207
1,504
1,957
1,832
1,924
350
1,103
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PCI in the ExTRACT-TIMI 25 Trial June 12, 2007:2238–46ardiac disease and procedures, time to presentation, initial
ital signs, infarct location, type of fibrinolytic agent, and
reatment allocation.
All statistical analyses were performed using Stata/SE,
ersion 9.0 (Stata Corp., College Station, Texas).
esults
total of 4,676 (23%) of the 20,479 patients in the
ntention to treat cohort in the ExTRACT–TIMI 25 trial
nderwent PCI by 30 days and represent the main cohort
or the present analysis (Fig. 1). There were significant
ifferences in the baseline characteristics of those patients
ho did and did not undergo PCI (Table 1), and a
ropensity score was developed to adjust for these differ-
nces (Table 2). This propensity score for performance of
CI included terms for age, earlier MI, earlier PCI, systolic
lood pressure and heart rate at presentation, earlier aspirin
se, history of hypertension, gender, anterior MI, time from
ymptom onset to administration of fibrinolytic agent, and
andomized treatment group and country (Table 2). The
-statistic for the propensity for performance of PCI model
as 0.82.
Among those patients treated with PCI, the 2 treatment
roups (ENOX vs. UFH) were similar with regard to
aseline characteristics (Table 3). The PCI was performed
n blinded study drug in 1,103 of 2,110 patients in the
NOX group (52.3%) and 1,075 of 2,238 patients in the
FH group (48.0%; p  0.005).
fficacy end points. INCIDENCE AND RELATIVE TIMING
F URGENT AND NONURGENT PCI. Enoxaparin was associ-
ted with a reduction in the frequency of PCI (22.8% vs.
4.2%; p  0.027) as well as a 12-h median delay in the
iming of performance of PCI (121.7 h vs. 109.2 h; p 
.006) (Fig. 2). Among patients who did not sustain
ecurrent ischemia or recurrent MI (i.e., among those
Figure 2 Kaplan-Meier Failure Estimates
for PCI by Randomization Group
PCI was performed less frequently in the ENOX group than
in the UFH group (p  0.02 by log rank). Abbreviations as in Figure 1.atients who underwent nonurgent PCI), there was noifference in the timing of the PCI (125.5 h for ENOX
n  1,885] vs. 120.3 h for UFH [n  1,829]; p  0.31).
mong patients in whom recurrent ischemia or recurrent
I preceded the PCI (urgent PCI), the recurrent ischemia
r MI and the ensuing PCI tended to occur later among
atients treated with ENOX compared with UFH (79.2 h
o PCI for ENOX [n  278] vs. 67.1 h to PCI for UFH
n  442]; p  0.08). Once a recurrent MI occurred, the
edian time to PCI did not differ between ENOX and
FH (2.2 h vs. 2.6 h, respectively; p 0.19). Therefore, the
verall 12-h delay in the performance of PCI among
NOX patients relative to UFH patients was attributable
rimarily to a delay in the occurrence of recurrent isch-
mia/MI that triggered a PCI among ENOX patients.
RIMARY EFFICACY COMPARISON OF ENOX VERSUS UFH.
mong patients treated with PCI, the rates of the primary
fficacy end point of death or nonfatal MI by 30 days were
ower in the ENOX group than in the UFH group (10.7%
f the ENOX vs. 13.8% of the UFH patients, 0.77 relative
isk, 95% CI 0.66 to 0.90; p 0.001) (Fig. 3, Table 4). This
ifference emerged before PCI and then persisted for up to
0 days. The reduction in death or nonfatal MI associated
ith ENOX administration remained statistically signifi-
ant after adjustment for age, earlier aspirin use, time to
CI, smoking, time from symptom onset to fibrinolytic
gent, type of fibrinolytic agent used (fibrin-specific or
treptokinase), and the propensity to undergo PCI (ORadj
.72, 95% CI 0.60 to 0.87; p  0.001). The association of
NOX with a reduction in death or MI among patients
ndergoing PCI was also consistent across a wide range of
ey subgroups (Fig. 4). Enoxaparin administration was asso-
iated with a significantly lower incidence of death or MI even
mong those patients treated with glycoprotein IIb/IIIa inhi-
ition (Fig. 4). Mortality did not differ by treatment group
2.9% for ENOX vs. 3.0% for UFH; p  0.922).
Figure 3 KM Failure for 30-Day Death or Recurrent MI
by Randomization Group in the PCI Cohort
Death or recurrent MI occurred less frequently in the ENOX group compared
with the UFH group in the PCI cohort (p  0.001 by log rank). KM  Kaplan-
Meier; MI  myocardial infarction; other abbreviations as in Figure 1.
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June 12, 2007:2238–46 PCI in the ExTRACT-TIMI 25 TrialNCIDENCE AND RELATIVE TIMING OF RECURRENT MI.
noxaparin administration was associated with a lower
ncidence of nonfatal recurrent MI among patients under-
oing PCI (7.8% vs. 10.9%, ORadj 0.69, 95% CI 0.56 to
.85; p 0.001). In addition to a reduction in the incidence
f recurrent MI in the ENOX group, the median time from
andomization to recurrent MI was 37 h longer with
NOX (95.8 vs. 58.3 h; p  0.04). Enoxaparin adminis-
ration was associated with a reduction in recurrent MI
efore PCI (Table 4).
CI PERFORMED DURING ACTIVE TREATMENT WITH
LINDED STUDY DRUG. In 2,178 patients, PCI was carried
ut while patients were receiving blinded study drug. The rate
f PCI performed on blinded study drug did not differ between
atients treated with ENOX and those with UFH (11.3%
1,103 of 9,788] vs. 11.0% [1,075 of 9,783]; p  0.53). There
as no difference in the time to PCI by treatment group during
he phase when patients were treated with blinded study drug
medians 63.6 h for ENOX vs. 58.7 h for UFH; p  0.45).
mong patients undergoing PCI on blinded study drug, death
r MI occurred less frequently in the ENOX group (13.0% vs.
6.7%, relative risk [RR] 0.77; p  0.013). The reduction in
eath or nonfatal MI associated with ENOX administration
emained statistically significant after adjustment for age,
arlier aspirin use, duration of antithrombin therapy before
CI, smoking, time from symptom onset to fibrinolytic agent,
ype of fibrinolytic agent used (fibrin-specific or streptokinase),
nd the propensity to undergo PCI (ORadj 0.68, 95% CI 0.53
o 0.87; p 0.002). There was no difference in major bleeding
1.8% with ENOX vs. 2.4% with UFH, RR 0.75; p  0.33).
Among the cohort of patients who had blinded study
rug discontinued before PCI and then resumed at the time
f PCI (1.7% for ENOX and 5.2% for UFH; p  0.001),
fficacy, Safety, and Net Clinical Benefit Outcomes by Treatment G
Table 4 Efficacy, Safety, and Net Clinical Benefit Outcomes by
ENOX (n  2,272)
Pre-PCI events, % (n)
MI 5.9 (133)
Stroke 0.04 (1)
Post-PCI events, % (n)
Death 2.9 (66)
MI 2.3 (53)
Stroke 0.2 (5)
All events through 30 days, % (n)
Death 2.9 (66)
MI 8.2 (187)
Stroke 0.3 (6)
TIMI major bleeding 1.4 (32)
TIMI major bleeding and died by 30 days 0.3 (7)
Intracranial hemorrhage 0.2 (4)
TIMI minor bleeding 3.3 (73)
TIMI major or minor bleeding 4.6 (103)
Death/nonfatal MI 10.7 (243)
Death/nonfatal MI/nonfatal major bleeding 11.5 (261)
bbreviations as in Tables 1 and 2.eath or MI occurred less frequently in the ENOX group than in the UFH group (5.9% vs. 14.4%, RR 0.41; p 
.004). Among the cohort of patients whose blinded study
rug was not discontinued before PCI (9.6% for ENOX and
.8% for UFH; p  0.001), death or MI occurred in 14.2%
f the ENOX group compared with 18.9% of the UFH
roup (RR 0.75; p  0.018).
afety end points. Among the 4,676 patients undergoing
CI within 30 days, the rates of TIMI major bleeding were
.4% in the ENOX group and 1.6% in the UFH group (RR
.87; p  0.56) (Table 4). There were also fewer strokes by
0 days in the ENOX group than in the UFH group (0.3%
s. 0.9%, RR 0.30; p  0.006), a finding that was evident
oth before and after the PCI (Table 4). The rates of
ntracranial hemorrhage were similar by treatment group
p  0.18). There were no differences in the rates of fatal
leeding, minor bleeding, and the composite of major or
inor bleeding between the ENOX and UFH groups
Table 4). Likewise, in the cohort of patients who under-
ent PCI while on treatment with blinded study drug, there
as no difference in the rate of bleeding (Table 5).
ET CLINICAL BENEFIT. The net clinical benefit composite
nd point of death, MI, or major bleeding was significantly
ower at 30 days in the ENOX group (Table 4), a reduction
n the absolute event rate of 3.3 absolute percentage points
nd an RR of 0.78 (p  0.001). In the patients who
nderwent PCI while on treatment with blinded study drug,
he net clinical end point was also lower by 4.3 absolute
ercentage points in the ENOX group (Table 5).
iscussion
mong STEMI patients who undergo PCI after fibrino-
ytic agent administration, a strategy of ENOX administra-
Among Patients Undergoing PCI by 30 Days
tment Group Among Patients Undergoing PCI by 30 Days
UFH (n  2,404) Relative Risk (95% CI) p Value
9.3 (223) 0.63 (0.51–0.78) 0.001
0.3 (7) 0.15 (0.02–1.23) 0.071
3.0 (71) 0.98 (0.71–1.37) 0.922
2.2 (53) 1.06 (0.73–1.54) 0.763
0.6 (14) 0.38 (0.14–1.05) 0.052
3.0 (71) 0.98 (0.71–1.37) 0.922
11.3 (272) 0.73 (0.61–0.87) 0.001
0.9 (21) 0.30 (0.12–0.75) 0.006
1.6 (39) 0.87 (0.55–1.39) 0.561
0.4 (10) 0.74 (0.28–1.95) 0.545
0.4 (10) 0.42 (0.13–1.35) 0.182
2.4 (58) 1.34 (0.95–1.88) 0.093
4.0 (95) 1.15 (0.88–1.51) 0.310
13.8 (332) 0.77 (0.66–0.90) 0.001
14.8 (355) 0.78 (0.67–0.90) 0.001roup
Treaion for the duration of the index hospitalization was
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PCI in the ExTRACT-TIMI 25 Trial June 12, 2007:2238–46uperior to one of UFH for 48 h as adjunctive antithrombin
herapy for the composite of efficacy and safety. One
uestion that arises is whether the efficacy of the ENOX
trategy was superior owing to its superiority as an anti-
hrombin or whether it was owing to a longer duration of
NOX infusion. In the cohort of patients undergoing PCI
uring the blinded study drug phase, when both ENOX and
FH had been administered for a similar duration (63.6 h
or ENOX vs. 58.7 h for UFH; p  0.45), the efficacy of
NOX as an antithrombin was superior to UFH (death/MI
Figure 4 Risk of 30-Day Death or Nonfatal Recurrent MI by Ran
Group According to Subgroups Among Patients Who U
GP  glycoprotein; Hx  history; SK  streptokinase; Sx  symptom; other abbre
utcomes by Treatment Group Among Patients Who Underwent PC
Table 5 Outcomes by Treatment Group Among Patients Who U
ENOX (n  1,103)
Individual end points
Death 3.8% (42)
MI 9.7% (107)
Stroke 0.4% (4)
TIMI major bleeding 1.8% (20)
TIMI minor bleeding 3.7% (41)
Composite end points
Death/nonfatal MI 13.0% (143)
Death/nonfatal MI/nonfatal major bleeding 14.0% (154)bbreviations as in Tables 1 and 2.4.2% vs. 18.9%, ORadj 0.68; p  0.002) without any
ncrease in fatal or nonfatal bleeding. Finally, the superiority
f ENOX was observed both among patients in whom study
rug was administered continuously up to and through the
erformance of PCI as well as in patients in whom study
rug was discontinued and then resumed for the perfor-
ance of PCI. Thus, the superiority of ENOX was ex-
lained at least in part by superior antithrombin efficacy
ather than simply a longer duration of therapy or due to
ebound associated with UFH discontinuation.
ization
went PCI
s as in Figures 1 and 3.
ile on Treatment With Blinded Study Drug
ent PCI While on Treatment With Blinded Study Drug
UFH (n  1,075) Relative Risk (95% CI) p Value
4.0% (43) 0.95 (0.63–1.44) 0.817
13.3% (143) 0.73 (0.58–0.92) 0.008
0.8% (9) 0.43 (0.13–1.40) 0.173
2.4% (26) 0.75 (0.42–1.34) 0.328
3.6% (39) 1.03 (0.67–1.58) 0.909
16.7% (180) 0.77 (0.63–0.95) 0.013
18.3% (197) 0.76 (0.63–0.92) 0.006dom
nder
viationI Wh
nderw
r
a
w
g
E
s
p
d
e
p
p
I
a
g
o
e
w
(
b
a
p
a
a
t
b
s
a
i
t
N
c
b
b
c
r
s
n
a
s
S
U
r
p
n
t
t
g
p
S
p
b
e
d
w
i
h
s
a
a
s
(
E
t
c
h
T
s
w
w
C
m
t
w
i
c
a
t
a
P
a
l
b
P
R
3
0
R
2245JACC Vol. 49, No. 23, 2007 Gibson et al.
June 12, 2007:2238–46 PCI in the ExTRACT-TIMI 25 TrialEnoxaparin administration was also associated with a
educed need for PCI (both during the blinded study drug
dministration phase and throughout 30 days) and likewise
ith deferred performance of PCI. The timing of nonur-
ent (i.e., elective) PCI did not differ between the UFH and
NOX arms, but urgent ischemia/recurrent MI that neces-
itated PCI tended to occur later and PCI was therefore
erformed later among patients treated with ENOX. This
elay in the occurrence of ischemia-driven PCI may be
specially beneficial in those patients who require interhos-
ital transfer as part of their management for STEMI.
Finally, the risk of stroke is often cited as a barrier to
erformance of PCI after fibrinolytic agent administration.
t is notable that ENOX administration was associated with
significantly lower incidence of stroke in patients under-
oing PCI, which adds to the favorable net clinical benefit
bserved with ENOX.
The favorable efficacy observed with ENOX may be
xplained by the agent’s superior antithrombin activity,
hich has been attributed to its greater anti-Xa:IIa ratio
9–11). It may also be explained by the rebound in throm-
otic events following discontinuation of UFH. The favor-
ble bleeding rates reported here may be explained at least in
art by the fact that few patients were switched between
ntithrombins from pre- to post-randomization. Addition-
lly, few patients crossed over from ENOX to UFH during
he PCI, with a large portion of patients remaining on
linded study drug at the time of PCI. It has been
peculated that both “switching” from pre-randomization
ssignment and “crossover” post-randomization accounted
n part for the excess bleeding observed among patients
reated with ENOX in SYNERGY (Superior Yield of the
ew Strategy of Enoxaparin, Revascularization, and Gly-
oprotein IIb/IIIa Inhibitors) (12), although a recent study
y Cohen et al. (13) did not demonstrate an increase in
leeding with switching. The results of the present PCI
ohort are similar to other recent studies showing compa-
able bleeding rates with ENOX and UFH in PCI (14,15).
Administration of ENOX also provided a seamless tran-
ition to the cardiac catheterization laboratory without the
eed for an additional antithrombin. The strategy of ENOX
lone as antithrombin monotherapy contrasts with the
trategies used in the OASIS (Organization to Assess
trategies for Ischemic Syndromes)-5 and -6 trials, in which
FH was administered in addition to ENOX or fondapa-
inux among patients undergoing PCI (16,17). In the
resent analysis, there was no excess bleeding (fatal or
onfatal) associated with ENOX compared with UFH as
he sole adjunctive antithrombin strategy. Despite the fact
hat the rate of bleeding was numerically lower for ENOX,
iven the infrequent nature of bleeding events the statistical
ower of such a comparison is limited.
tudy limitations. This is an analysis of a subgroup of
atients in a randomized trial, and as such it is possible that
oth identified and unidentified confounders may have influ-
nced the outcomes. The decision to perform PCI was at theiscretion of the investigator. The ExTRACT-TIMI 25 trial
as a comparison of a strategy of ENOX given through the
ndex hospitalization compared with UFH given for at least 48
ours. Therefore, differences in outcomes between the 2
trategies may reflect differences in the type of anticoagulant
s well as the duration of treatment. However, in the
nalysis of patients who underwent PCI while on blinded
tudy drug, despite no difference in the duration of therapy
median 63.6 h for ENOX vs. 58.7 h for UFH; p  0.45),
NOX was associated with a reduction in death or MI
hrough 30 days compared with UFH. Strict enrollment
riteria are used in clinical trials, and the results observed
ere may not be applicable to all patients in clinical practice.
he pre-PCI patency status of the vessel was not recorded,
o it could not be determined whether an occluded artery
as being opened (“rescue PCI”), or whether an open artery
as dilated (“adjunctive PCI”).
linical implications. Compared with UFH, ENOX ad-
inistration as an adjunct to fibrinolytic agent administra-
ion was associated with significantly fewer pre-PCI MIs as
ell as fewer strokes among patients with STEMI. Admin-
stration of ENOX provided a seamless transition to the
ardiac catheterization laboratory without the need for an
dditional antithrombin. Adjunctive ENOX as adminis-
ered in this study is preferred to UFH as the adjunctive
ntithrombin regimen to support a practice pattern in which
CI is performed at some time after fibrinolytic agent
dministration. Enoxaparin was associated with both de-
ayed onset and reduced recurrence of MI, and both of these
enefits may expand the window of opportunity to perform
CI after fibrinolytic agent administration.
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50 Longwood Avenue, First Floor, Boston, Massachusetts
2115. E-mail: eantman@rics.bwh.harvard.edu.
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